Role of cardiac magnetic resonance imaging in assessment of nonischemic cardiomyopathies

Topics in Magnetic Resonance Imaging

Volumn 19, Issue 1, 2008, Pages 43-57

  Shehata, Monda L ^a   Turkbey, Evrim B ^a   Vogel Claussen, Jens ^a   Bluemke, David A ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Cardiac; Cardiomyopathy; CMR; DE CMR; MRI

Indexed keywords

AMYLOIDOSIS; ANDERSON FABRY; ARTICLE; CARDIAC MAGNETIC RESONANCE IMAGING; CARDIOMYOPATHY; CHAGAS DISEASE; CLINICAL ASSESSMENT; CONGESTIVE CARDIOMYOPATHY; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; ECHOCARDIOGRAPHY; ENDOCARDIAL FIBROELASTOSIS; HEART RIGHT VENTRICLE DYSPLASIA; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; LYSOSOME STORAGE DISEASE; MUSCULAR DYSTROPHY; MYOCARDITIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SARCOIDOSIS; SENSITIVITY AND SPECIFICITY; SUDDEN DEATH; TAKOTSUBO CARDIOMYOPATHY; COMPUTER ASSISTED DIAGNOSIS; FEMALE; HEART MUSCLE; MALE; METHODOLOGY; PATHOLOGY; RESTRICTIVE CARDIOMYOPATHY; REVIEW;

ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA; CARDIOMYOPATHIES; CARDIOMYOPATHY, DILATED; CARDIOMYOPATHY, HYPERTROPHIC; CARDIOMYOPATHY, RESTRICTIVE; CHAGAS CARDIOMYOPATHY; FEMALE; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE IMAGING, CINE; MALE; MYOCARDIUM; SENSITIVITY AND SPECIFICITY;

EID: 54049126208     PISSN: 08993459     EISSN: None     Source Type: Journal    
DOI: 10.1097/RMR.0b013e31816fcb22     Document Type: Article

References (129)

1. Maron BJ, Towbin JA, Thiene G, et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation. 2006;113:1807-1816.
2. Richardson P, McKenna W, Bristow M, et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the definition and classification of cardiomyopathies. Circulation. 1996;93:841-842.
3. Gottlieb I, Macedo R, Bluemke DA, et al. Magnetic resonance imaging in the evaluation of non-ischemic cardiomyopathies: current applications and future perspectives. Heart Fail Rev. 2006;11: 313-323.
4. Macedo R, Schmidt A, Rochitte CE, et al. MRI to assess arrhythmia and cardiomyopathies: relationship to echocardiography. Echocardiography. 2007;24:194-206.
5. Bogaert J, Dymarkowski S, Taylor AM. Clinical cardiac MRI. Berlin: Springer, 2005:549 p.
6. Matsuoka H, Hamada M, Honda T, et al. Precise assessment of myocardial damage associated with secondary cardiomyopathies by use of Gd-DTPA-enhanced magnetic resonance imaging. Angiology. 1993;44:945-950.
7. Macedo R, Schmidt A, Rochitte CE, et al. MRI to assess arrhythmia and cardiomyopathies. J Magn Reson Imaging. 2006;24:1197-1206.
8. Zerhouni EA, Parish DM, Rogers WJ, et al. Human heart: tagging with MR imaging - a method for noninvasive assessment of myocardial motion. Radiology. 1988;169:59-63.
9. Pennell DJ, Sechtem UP, Higgins CB, et al. Clinical indications for cardiovascular magnetic resonance (CMR): consensus panel report. J Cardiovasc Magn Reson. 2004;6:727-765.
10. Maron MS, Hauser TH, Dubrow E, et al. Right ventricular involvement in hypertrophic cardiomyopathy. Am J Cardiol. 2007; 100:1293-1298.
11. Mozaffarian D, Caldwell JH. Right ventricular involvement in hypertrophic cardiomyopathy: a case report and literature review. Clin Cardiol. 2001;24:2-8.
12. Rickers C, Wilke NM, Jerosch-Herold M, et al. Utility of cardiac magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy. Circulation. 2005;112:855-861.
13. Moon JC, Fisher NG, McKenna WJ, et al. Detection of apical hypertrophic cardiomyopathy by cardiovascular magnetic resonance in patients with non-diagnostic echocardiography. Heart. 2004;90:645-649.
14. Spirito P, Bellone P, Harris KM, et al. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med. 2000;342:1778-1785.
15. Sorajja P, Nishimura RA, Ommen SR, et al. Use of echocardiography in patients with hypertrophic cardiomyopathy: clinical implications of massive hypertrophy. J Am Soc Echocardiogr. 2006;19:788-795.
16. Soler R, Rodriguez E, Marini M. Left ventricular mass in hypertrophic cardiomyopathy: assessment by three-dimensional and geometric MR methods. J Comput Assist Tomogr. 1999;23:577-582.
17. Woo A, Williams WG, Choi R, et al. Clinical and echocardiographic determinants of long-term survival after surgical myectomy in obstructive hypertrophic cardiomyopathy. Circulation. 2005; 111:2033-2041.
18. Varnava AM, Elliott PM, Mahon N, et al. Relation between myocyte disarray and outcome in hypertrophic cardiomyopathy. Am J Cardiol. 2001;88:275-279.
19. Choudhury L, Mahrholdt H, Wagner A, et al. Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2002;40:2156-2164.
20. van Dockum WG, ten Cate FJ, ten Berg JM, et al. Myocardial infarction after percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: evaluation by contrast-enhanced magnetic resonance imaging. J Am Coll Cardiol. 2004;43:27-34.
21. Sipola P, Lauerma K, Husso-Saastamoinen M, et al. First-pass MR imaging in the assessment of perfusion impairment in patients with hypertrophic cardiomyopathy and the Asp175Asn mutation of the alpha-tropomyosin gene. Radiology. 2003;226:129-137.
22. Dong SJ, MacGregor JH, Crawley AP, et al. Left ventricular wall thickness and regional systolic function in patients with hypertrophic cardiomyopathy. A three-dimensional tagged magnetic resonance imaging study. Circulation. 1994;90:1200-1209.
23. Kramer CM, Reichek N, Ferrari VA, et al. Regional heterogeneity of function in hypertrophic cardiomyopathy. Circulation. 1994; 90:186-194.
24. Young AA, Kramer CM, Ferrari VA, et al. Three-dimensional left ventricular deformation in hypertrophic cardiomyopathy. Circulation. 1994;90:854-867.
25. Jung W-I, Sieverding L, Breuer J, et al. 31P NMR spectroscopy detects metabolic abnormalities in asymptomatic patients with hypertrophic cardiomyopathy. Circulation. 1998;97:2536-2542.
26. Crilley JG, Boehm EA, Blair E, et al. Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy. J Am Coll Cardiol. 2003;41:1776-1782.
27. Ennis DB, Epstein FH, Kellman P, et al. Assessment of regional systolic and diastolic dysfunction in familial hypertrophic cardiomyopathy using MR tagging. Magn Reson Med. 2003; 50:638-642.
28. van Dockum WG, Kuijer JP, Gotte MJ, et al. Septal ablation in hypertrophic obstructive cardiomyopathy improves systolic myocardial function in the lateral (free) wall: a follow-up study using CMR tissue tagging and 3D strain analysis. Eur Heart J. 2006;27: 2833-2839.
29. Gerull B, Heuser A, Wichter T, et al. Mutations in the desmosomal protein plakophilin-2 are common in arrhythmogenic right ventricular cardiomyopathy. Nat Genet. 2004;36:1162-1164.
30. Syrris P, Ward D, Asimaki A, et al. Clinical expression of plakophilin-2 mutations in familial arrhythmogenic right ventricular cardiomyopathy. Circulation. 2006;113:356-364.
31. Pinamonti B, Sinagra G, Salvi A, et al. Left ventricular involvement in right ventricular dysplasia. Am Heart J. 1992;123:711-724.
32. Sen-Chowdhry S, Syrris P, Ward D, et al. Clinical and genetic characterization of families with arrhythmogenic right ventricular dysplasia/cardiomyopathy provides novel insights into patterns of disease expression. Circulation. 2007;115:1710-1720.
33. Marcus FI, Fontaine GH, Guiraudon G, et al. Right ventricular dysplasia: a report of 24 adult cases. Circulation. 1982;65:384-398.
34. McKenna WJ, Thiene G, Nava A, et al. Diagnosis of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Task Force of the Working Group Myocardial and Pericardial Disease of the European Society of Cardiology and of the Scientific Council on Cardiomyopathies of the International Society and Federation of Cardiology. Br Heart J. 1994;71:215-218.
35. Tandri H, Saranathan M, Rodriguez ER, et al. Noninvasive detection of myocardial fibrosis in arrhythmogenic right ventricular cardiomyopathy using delayed-enhancement magnetic resonance imaging. J Am Coll Cardiol. 2005;45:98-103.
36. Desai MY, Gupta S, Bomma C, et al. The apparent inversion time for optimal delayed enhancement magnetic resonance imaging differs between the right and left ventricles. J Cardiovasc Magn Reson. 2005;7:475-479.
37. White JA, Patel MR. The role of cardiovascular MRI in heart failure and the cardiomyopathies. Cardiol Clin. 2007;25:71-95, vi.
38. Auffermann W, Wichter T, Breithardt G, et al. Arrhythmogenic right ventricular disease: MR imaging vs angiography. Am J Roentgenol. 1993;161:549-555.
39. Bluemke DA, Krupinski EA, Ovitt T, et al. MR imaging of arrhythmogenic right ventricular cardiomyopathy: morphologic findings and interobserver reliability. Cardiology. 2003;99:153-162.
40. Macedo R, Prakasa K, Tichnell C, et al. Marked lipomatous infiltration of the right ventricle: MRI findings in relation to arrhythmogenic right ventricular dysplasia. Am J Roentgenol. 2007;188:W423-W427.
41. Tandri H, Calkins H, Nasir K, et al. Magnetic resonance imaging findings in patients meeting task force criteria for arrhythmogenic right ventricular dysplasia. J Cardiovasc Electrophysiol. 2003;14: 476-482.
42. Tandri H, Castillo E, Ferrari VA, et al. Magnetic resonance imaging of arrhythmogenic right ventricular dysplasia: sensitivity, specificity, and observer variability of fat detection versus functional analysis of the right ventricle. J Am Coll Cardiol. 2006;48:2277-2284.
43. Bomma C, Rutberg J, Tandri H, et al. Misdiagnosis of arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Cardiovasc Electrophysiol. 2004;15:300-306.
44. Tandri H, Bluemke DA, Ferrari VA, et al. Findings on magnetic resonance imaging of idiopathic right ventricular outflow tachycardia. Am J Cardiol. 2004;94:1441-1445.
45. Grimm W, ListHellwig E, Hoffmann J, et al. Magnetic resonance imaging and signal-averaged electrocardiography in patients with repetitive monomorphic ventricular tachycardia and otherwise normal electrocardiogram. 1997;20:1826-1833.
46. White RD, Trohman RG, Flamm SD, et al. Right ventricular arrhythmia in the absence of arrhythmogenic dysplasia: MR imaging of myocardial abnormalities. Radiology. 1998;207:743-751.
47. Proclemer A, Basadonna PT, Slavich GA, et al. Cardiac magnetic resonance imaging findings in patients with right ventricular outflow tract premature contractions. Eur Heart J. 1997;18:2002-2010.
48. Globits S, Kreiner G, Frank H, et al. Significance of morphological abnormalities detected by MRI in patients undergoing successful ablation of right ventricular outflow tract tachycardia. Circulation. 1997;96:2633-2640.
49. Razmi RM. Magnetic resonance imaging findings in patients with Brugada syndrome. J Cardiovasc Electrophysiol. 2004;15:1139-1140.
50. Oechslin EN, Attenhofer Jost CH, Rojas JR, et al. Long-term follow-up of 34 adults with isolated left ventricular noncompaction: a distinct cardiomyopathy with poor prognosis. J Am Coll Cardiol. 2000; 36:493-500.
51. Petersen SE, Selvanayagam JB, Wiesmann F, et al. Left ventricular non-compaction: insights from cardiovascular magnetic resonance imaging. J Am Coll Cardiol. 2005;46:101-105.
52. Dodd JD, Holmvang G, Hoffmann U, et al. Quantification of left ventricular noncompaction and trabecular delayed hyperenhancement with cardiac MRI: correlation with clinical severity. AJR Am J Roentgenol. 2007;189:974-980.
53. Strohm O, Schulz-Menger J, Pilz B, et al. Measurement of left ventricular dimensions and function in patients with dilated cardiomyopathy. J Magn Reson Imaging. 2001;13:367-371.
54. Schulz-Menger J, Friedrich MG. Magnetic resonance imaging in patients with cardiomyopathies: when and why. Herz. 2000;25:384-391.
55. Soler R, Rodriguez E, Remuinan C, et al. Magnetic resonance imaging of primary cardiomyopathies. J Comput Assist Tomogr. 2003; 27:724-734.
56. MacGowan GA, Shapiro EP, Azhari H, et al. Noninvasive measurement of shortening in the fiber and cross-fiber directions in the normal human left ventricle and in idiopathic dilated cardiomyopathy. Circulation. 1997;96:535-541.
57. Wu E, Judd RM, Vargas JD, et al. Visualisation of presence, location, and transmural extent of healed Q-wave and non-Q-wave myocardial infarction. Lancet. 2001;357:21-28.
58. McCrohon JA, Moon JC, Prasad SK, et al. Differentiation of heart failure related to dilated cardiomyopathy and coronary artery disease using gadolinium-enhanced cardiovascular magnetic resonance. Circulation. 2003;108:54-59.
59. Zimmermann O, Grebe O, Merkle N, et al. Myocardial biopsy findings and gadolinium enhanced cardiovascular magnetic resonance in dilated cardiomyopathy. Eur J Heart Fail. 2006;8:162-166.
60. Calore C, Cacciavillani L, Boffa GM, et al. Contrast-enhanced cardiovascular magnetic resonance in primary and ischemic dilated cardiomyopathy. J Cardiovasc Med. 2007;8:821-829.
61. Matoh F, Satoh H, Shiraki K, et al. Usefulness of delayed enhancement magnetic resonance imaging to differentiate dilated phase of hypertrophic cardiomyopathy and dilated cardiomyopathy. J Card Fail. 2007;13:372-379.
62. Grimm W, Alter P, Maisch B. Arrhythmia risk stratification with regard to prophylactic implantable defibrillator therapy in patients with dilated cardiomyopathy. Results of MACAS, DEFINITE, and SCD-HeFT. Herz. 2004;29:348-352.
63. Nazarian S, Bluemke DA, Lardo AC, et al. Magnetic resonance assessment of the substrate for inducible ventricular tachycardia in nonischemic cardiomyopathy. Circulation. 2005;112:2821-2825.
64. Assomull RG, Prasad SK, Lyne J, et al. Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. J Am Coll Cardiol. 2006;48:1977-1985.
65. Rochitte CE, Nacif MS, de Oliveira Junior AC, et al. Cardiac magnetic resonance in Chagas' disease. Artif Organs. 2007;31:259-267.
66. Patel RA, DiMarco JP, Akar JG, et al. Chagas myocarditis and syncope. J Cardiovasc Magn Reson. 2005;7:685-688.
67. Marin Neto JA, Simoes MV, Sarabanda AV. Chagas' heart disease. Arq Bras Cardiol. 1999;72:247-280.
68. Rochitte CE, Oliveira PF, Andrade JM, et al. Myocardial delayed enhancement by magnetic resonance imaging in patients with Chagas' disease: a marker of disease severity. J Am Coll Cardiol. 2005;46:1553-1558.
69. Asher CR, Klein AL. Diastolic heart failure: restrictive cardiomyopathy, constrictive pericarditis, and cardiac tamponade: clinical and echocardiographic evaluation. Cardiol Rev. 2002;10:218-229.
70. Masui T, Finck S, Higgins CB. Constrictive pericarditis and restrictive cardiomyopathy: evaluation with MR imaging. Radiology. 1992;182: 369-373.
71. Francone M, Dymarkowski S, Kalantzi M, et al. Assessment of ventricular coupling with real-time cine MRI and its value to differentiate constrictive pericarditis from restrictive cardiomyopathy. Eur Radiol. 2006;16:944-951.
72. Feldman AM, McNamara D. Myocarditis. N Engl J Med. 2000;343: 1388-1398.
73. Pinamonti B, Alberti E, Cigalotto A, et al. Echocardiographic findings in myocarditis. Am J Cardiol. 1988;62:285-291.
74. Isbell DC, Kramer CM. The evolving role of cardiovascular magnetic resonance imaging in nonischemic cardiomyopathy. Semin Ultrasound CT MR. 2006;27:20-31.
75. Friedrich MG, Strohm O, Schulz-Menger J, et al. Contrast media-enhanced magnetic resonance imaging visualizes myocardial changes in the course of viral myocarditis. Circulation. 1998; 97:1802-1809.
76. Roditi GH, Hartnell GG, Cohen MC. MRI changes in myocarditis - evaluation with spin echo, cine MR angiography and contrast enhanced spin echo imaging. Clin Radiol. 2000;55:752-758.
77. Mahrholdt H, Goedecke C, Wagner A, et al. Cardiovascular magnetic resonance assessment of human myocarditis: a comparison to histology and molecular pathology. Circulation. 2004;109:1250-1258.
78. Abdel-Aty H, Boye P, Zagrosek A, et al. Diagnostic performance of cardiovascular magnetic resonance in patients with suspected acute myocarditis: comparison of different approaches. J Am Coll Cardiol. 2005;45:1815-1822.
79. Laissy JP, Hyafil F, Feldman LJ, et al. Differentiating acute myocardial infarction from myocarditis: diagnostic value of early- and delayed-perfusion cardiac MR imaging. Radiology. 2005;237:75-82.
80. Wagner A, Schulz-Menger J, Dietz R, et al. Long-term follow-up of patients paragraph sign with acute myocarditis by magnetic paragraph sign resonance imaging. MAGMA. 2003;16:17-20.
81. Codreanu A, Djaballah W, Angioi M, et al. Detection of myocarditis by contrast-enhanced MRI in patients presenting with acute coronary syndrome but no coronary stenosis. J Magn Reson Imaging. 2007;25:957-964.
82. Fritz J, Wittstein IS, Lima JA, et al. Transient left ventricular apical ballooning: magnetic resonance imaging evaluation. J Comput Assist Tomogr. 2005;29:34-36.
83. Nef HM, Mollmann H, Elsasser A. Tako-tsubo cardiomyopathy (apical ballooning). Heart. 2007;93:1309-1315.
84. Cocco G, Chu D. Stress-induced cardiomyopathy: a review. Eur J Int Med. 2007;18:369-379.
85. Haghi D, Fluechter S, Suselbeck T, et al. Cardiovascular magnetic resonance findings in typical versus atypical forms of the acute apical ballooning syndrome (takotsubo cardiomyopathy). Int J Cardiol. 2007;120:205-211.
86. Haghi D, Papavassiliu T, Fluchter S, et al. Variant form of the acute apical ballooning syndrome (takotsubo cardiomyopathy): observations on a novel entity. Heart. 2006;92:392-394.
87. Haghi D, Athanasiadis A, Papavassiliu T, et al. Right ventricular involvement in Takotsubo cardiomyopathy. Eur Heart J. 2006;27:2433-2439.
88. Deetjen AG, Conradi G, Mollmann S, et al. Value of gadolinium-enhanced magnetic resonance imaging in patients with Tako-Tsubo-like left ventricular dysfunction. J Cardiovasc Magn Reson. 2006;8:367-372.
89. Mitchell JH, Hadden TB, Wilson JM, et al. Clinical features and usefulness of cardiac magnetic resonance imaging in assessing myocardial viability and prognosis in Takotsubo cardiomyopathy (transient left ventricular apical ballooning syndrome). Am J Cardiol. 2007;100:296-301.
90. Pearson GD, Veille JC, Rahimtoola S, et al. Peripartum cardiomyopathy: National Heart, Lung, and Blood Institute and Office of Rare Diseases (National Institutes of Health) workshop recommendations and review. JAMA. 2000;283:1183-1188.
91. Abboud J, Murad Y, Chen-Scarabelli C, et al. Peripartum ardiomyopathy: a comprehensive review. Int J Cardiol. 2007; 118:295-303.
92. Expert consensus document on management of cardiovascular diseases during pregnancy. Eur Heart J. 2003;24:761-781.
93. Kholova I, Niessen HW. Amyloid in the cardiovascular system: a review. J Clin Pathol. 2005;58:125-133.
94. Kushwaha SS, Fallon JT, Fuster V. Restrictive cardiomyopathy. N Engl J Med. 1997;336:267-276.
95. Maceira AM, Joshi J, Prasad SK, et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation. 2005;111:186-193.
96. Fattori R, Rocchi G, Celletti F, et al. Contribution of magnetic resonance imaging in the differential diagnosis of cardiac amyloidosis and symmetric hypertrophic cardiomyopathy. Am Heart J. 1998; 136:824-830.
97. Pennell DJ, Sechtem UP, Higgins CB, et al. Clinical indications for cardiovascular magnetic resonance (CMR): consensus panel report. Eur Heart J. 2004;25:1940-1965.
98. Strotmann J, Weidemann F, Breunig F, et al. Morbus Fabry of the heart. Why should cardiologists care? Z Kardiol. 2005;94:557-563.
99. Moon JC, Sachdev B, Elkington AG, et al. Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium. Eur Heart J. 2003;24:2151-2155.
100. Moon JC, Sheppard M, Reed E, et al. The histological basis of late gadolinium enhancement cardiovascular magnetic resonance in a patient with Anderson-Fabry disease. J Cardiovasc Magn Reson. 2006;8:479-482.
101. Beer M, Weidemann F, Breunig F, et al. Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry's cardiomyopathy. Am J Cardiol. 2006;97:1515-1518.
102. Raman SV, Mehta R, Walker J, et al. Cardiovascular magnetic resonance in endocardial fibroelastosis. J Cardiovasc Magn Reson. 2005;7:391-393.
103. Petersen SE, Kardos A, Neubauer S. Subendocardial and papillary muscle involvement in a patient with Churg-Strauss syndrome, detected by contrast enhanced cardiovascular magnetic resonance. Heart. 2005;91:E9.
104. Alter P, Maisch B. Endomyocardial fibrosis in Churg-Strauss syndrome assessed by cardiac magnetic resonance imaging. Int J Cardiol. 2006;108:112-113.
105. Nemeth MA, Muthupillai R, Wilson JM, et al. Cardiac sarcoidosis detected by delayed-hyperenhancement magnetic resonance imaging. Tex Heart Inst J. 2004;31:99-102.
106. Sharma OP, Maheshwari A, Thaker K. Myocardial sarcoidosis. Chest. 1993;103:253-258.
107. Smedema JP, Snoep G, van Kroonenburgh MP, et al. Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis. J Am Coll Cardiol. 2005;45:1683-1690.
108. Lewin RF, Mor R, Spitzer S, et al. Echocardiographic evaluation of patients with systemic sarcoidosis. Am Heart J. 1985;110:116-122.
109. Ratner SJ, Fenoglio JJ, Jr, Ursell PC. Utility of endomyocardial biopsy in the diagnosis of cardiac sarcoidosis. Chest. 1986;90:528-533.
110. Saeki M, Kitazawa H, Kodama M, et al. Images in cardiovascular medicine. Cardiac sarcoidosis. 67Ga imaging and histology. Circulation. 1995;91:2497-2498.
111. Vignaux O, Dhote R, Duboc D, et al. Detection of myocardial involvement in patients with sarcoidosis applying T2-weighted, contrast-enhanced, and cine magnetic resonance imaging: initial results of a prospective study. J Comput Assist Tomogr. 2002; 26:762-767.
112. Vignaux O, Dhote R, Duboc D, et al. Clinical significance of myocardial magnetic resonance abnormalities in patients with sarcoidosis: a 1-year follow-up study. Chest. 2002;122:1895-1901.
113. Smedema JP, Snoep G, van Kroonenburgh MP, et al. The additional value of gadolinium-enhanced MRI to standard assessment for cardiac involvement in patients with pulmonary sarcoidosis. Chest. 2005; 128:1629-1637.
114. Borchert B, Lawrenz T, Bartelsmeier M, et al. Utility of endomyocardial biopsy guided by delayed enhancement areas on magnetic resonance imaging in the diagnosis of cardiac sarcoidosis. Clin Res Cardiol. 2007;96:759-762.
115. Varghese A, Pennell DJ. Late gadolinium enhanced cardiovascular magnetic resonance in Becker muscular dystrophy. Heart. 2004; 90:E59.
116. Finsterer J, Stollberger C. Cardiac involvement in primary myopathies. Cardiology. 2000;94:1-11.
117. Ashford MW, Jr, Liu W, Lin SJ, et al. Occult cardiac contractile dysfunction in dystrophin-deficient children revealed by cardiac magnetic resonance strain imaging. Circulation. 2005;112:2462-2467.
118. Petrie CJ, Mark PB, Dargie HJ. Cardiomyopathy in Becker muscular dystrophy - does regional fibrosis mimic infarction? J Cardiovasc Magn Reson. 2005;7:823-825.
119. Silva MC, Meira ZM, Gurgel Giannetti J, et al. Myocardial delayed enhancement by magnetic resonance imaging in patients with muscular dystrophy. J Am Coll Cardiol. 2007;49:1874-1879.
120. Crilley JG, Boehm EA, Rajagopalan B, et al. Magnetic resonance spectroscopy evidence of abnormal cardiac energetics in Xp21 muscular dystrophy. J Am Coll Cardiol. 2000;36:1953-1958.
121. Maceira AM, Prasad SK, Pennell DJ, et al. Integrated evaluation of hypertensive patients with cardiovascular magnetic resonance. Int J Cardiol. 2007.
122. Alfakih K, Bloomer T, Bainbridge S, et al. A comparison of left ventricular mass between two-dimensional echocardiography, using fundamental and tissue harmonic imaging, and cardiac MRI in patients with hypertension. Eur J Radiol. 2004;52:103-109.
123. Laurent S, Boutouyrie P, Asmar R, et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension. 2001;37:1236-1241.
124. Marcus JT, Vonk Noordegraaf A, Roeleveld RJ, et al. Impaired left ventricular filling due to right ventricular pressure overload in primary pulmonary hypertension: noninvasive monitoring using MRI. Chest. 2001;119:1761-1765.
125. Nagendran J, Michelakis E. MRI: one-stop shop for the comprehensive assessment of pulmonary arterial hypertension? Chest. 2007;132:2-5.
126. Vonk-Noordegraaf A, Marcus JT, Gan CT, et al. Interventricular mechanical asynchrony due to right ventricular pressure overload in pulmonary hypertension plays an important role in impaired left ventricular filling. Chest. 2005;128:628S-630S.
127. Blyth KG, Groenning BA, Martin TN, et al. Contrast enhanced- cardiovascular magnetic resonance imaging in patients with pulmonary hypertension. Eur Heart J. 2005;26:1993-1999.
128. Sanz J, Kuschnir P, Rius T, et al. Pulmonary arterial hypertension: noninvasive detection with phase-contrast MR imaging. Radiology. 2007;243:70-79.
129. Ohno Y, Hatabu H, Murase K, et al. Primary pulmonary hypertension: 3D dynamic perfusion MRI for quantitative analysis of regional pulmonary perfusion. AJR Am J Roentgenol. 2007;188:48-56.